Compare PAVM & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAVM | SCLX |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | United States | United States |
| Employees | 41 | 34 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.1M | 48.5M |
| IPO Year | N/A | N/A |
| Metric | PAVM | SCLX |
|---|---|---|
| Price | $6.42 | $6.81 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $65.00 | N/A |
| AVG Volume (30 Days) | 14.0K | ★ 88.8K |
| Earning Date | 05-15-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $603.94 | $122.52 |
| Revenue Next Year | $33.16 | $186.30 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.21 | $4.09 |
| 52 Week High | $28.44 | $34.27 |
| Indicator | PAVM | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 31.54 | 41.81 |
| Support Level | $6.11 | $6.20 |
| Resistance Level | $10.98 | $8.18 |
| Average True Range (ATR) | 0.43 | 1.38 |
| MACD | -0.18 | -0.29 |
| Stochastic Oscillator | 11.93 | 7.30 |
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, EsoCheck, and the Veris Cancer Care Platform.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.